Followers | 507 |
Posts | 10138 |
Boards Moderated | 0 |
Alias Born | 04/28/2014 |
Tuesday, March 22, 2016 11:04:55 AM
bullish 2.20
$ATNM charts
basic chart ## source: stockcharts.com
basic chart ## source: stockscores.com
big daily chart ## source: stockcharts.com
big weekly chart ## source: stockcharts.com
$ATNM company information
## source: otcmarkets.com
Link: http://www.otcmarkets.com/stock/ATNM/company-info
Ticker: $ATNM
$ATNM extra dd links
## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/ATNM/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/ATNM/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=ATNM+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=ATNM+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=ATNM+Industry
## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/ATNM/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/ATNM/news - http://finance.yahoo.com/q/h?s=ATNM+Headlines
## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/ATNM/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/ATNM/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/ATNM/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/ATNM/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/ATNM/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/ATNM/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/ATNM/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/ATNM/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=ATNM+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/ATNM
## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/ATNM/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/ATNM
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/ATNM/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/ATNM/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/ATNM/sec-filings
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/ATNM/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/ATNM/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/ATNM/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/ATNM/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=ATNM&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=ATNM
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/ATNM/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=ATNM+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=ATNM+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=ATNM
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=ATNM
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=ATNM+Cash+Flow&annual
## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/ATNM/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=ATNM+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/ATNM.ATNM
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=ATNM
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/ATNM/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/ATNM/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/ATNM/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/ATNM/insider-transactions
## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/ATNM
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/ATNM
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/ATNM:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=ATNM
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=ATNM
Recent ATNM News
- Actinium Highlights Ability of Iomab-B to Overcome High-Risk TP53 Mutation Resulting in Significant Improvement in Overall Survival in Patients with Active Relapsed Refractory AML at the European Bone Marrow Transplant Annual Meeting • PR Newswire (US) • 04/18/2024 12:00:00 PM
- Actinium Announces Iomab-B Phase 3 SIERRA Trial Results Demonstrating Survival Benefit in High-Risk Relapsed or Refractory Acute Myeloid Leukemia Patients with TP53 Mutations Accepted for Oral Presentation at the 50th European Bone Marrow Transplant Annual • PR Newswire (US) • 04/01/2024 12:00:00 PM
- Actinium Announces Clinical Trial to Study Iomab-ACT Targeted Radiotherapy Conditioning with Leading FDA Approved Commercial CAR T-Cell Therapy • PR Newswire (US) • 03/26/2024 11:18:00 AM
- Actinium Pharmaceuticals Launches Actinium-225 Focused Strategic Initiative to Leverage Proprietary Cyclotron Based Manufacturing Technology to Address Growing Market Demand • PR Newswire (US) • 03/11/2024 11:30:00 AM
- Actinium Announces Iomab-B Markedly Increases Long Term Survival in Patients 65 Years or Older with Active Relapsed or Refractory AML in the Phase 3 SIERRA Trial at the 2024 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT® and CIBMT • PR Newswire (US) • 02/26/2024 12:30:00 PM
- Actinium Highlights Improved Survival with Iomab-B in TP53 Positive Relapsed Refractory Acute Myeloid Leukemia Patients in the SIERRA Trial and Other Presentations at the 2024 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT® and CIB • PR Newswire (US) • 02/23/2024 12:30:00 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/09/2024 09:30:19 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 02/06/2024 05:15:04 AM
- Form S-3/A - Registration statement under Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 02/02/2024 10:03:47 PM
- Actinium Announces Acceptance of Five Abstracts for Presentation at the 2024 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT® and CIBMTR® • PR Newswire (US) • 01/02/2024 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/29/2023 10:24:56 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/29/2023 10:20:23 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/29/2023 10:18:40 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/29/2023 10:17:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/29/2023 10:15:37 PM
- Actinium Announces Iomab-B Produces High Response Rates and Significant Improvement in Overall Survival in Relapsed Refractory AML Patients with Active Disease Overcoming TP53 Mutation • PR Newswire (US) • 12/11/2023 01:15:00 PM
- Actinium's Four Presentations at ASH Highlight the Positive Outcomes for Iomab-B and Actimab-A in Patients with Relapsed or Refractory Acute Myeloid Leukemia • PR Newswire (US) • 12/11/2023 12:45:00 PM
- Actinium to Highlight Broad Potential of Targeted Radiotherapies Iomab-B and Actimab-A for Relapsed or Refractory and Elderly Acute Myeloid Leukemia Patients at the 65th ASH Annual Meeting & Exposition • PR Newswire (US) • 12/08/2023 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/01/2023 10:00:19 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/09/2023 10:05:10 PM
- Actinium Presents Preclinical Data at SITC Demonstrating Actimab-A's Potential to Restore T Cell Immunity in the Solid Tumor Microenvironment Supporting Immunotherapy Combinations • PR Newswire (US) • 11/06/2023 12:30:00 PM
- Actinium Pharmaceuticals to Attend Bio-Europe Munich 2023 • PR Newswire (US) • 11/02/2023 08:15:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/02/2023 01:05:39 PM
- Actinium Announces Oral Presentation at ASH Annual Meeting Highlighting Iomab-B Treatment Significantly Increased Median Overall Survival in Relapsed or Refractory AML Patients with Highly Unfavorable TP53 Gene Mutation in the Phase 3 SIERRA Trial • PR Newswire (US) • 11/02/2023 01:05:00 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM